DK549685D0 - Difluornucleosider til behandling af neoplasma hos pattedyr - Google Patents

Difluornucleosider til behandling af neoplasma hos pattedyr

Info

Publication number
DK549685D0
DK549685D0 DK549685A DK549685A DK549685D0 DK 549685 D0 DK549685 D0 DK 549685D0 DK 549685 A DK549685 A DK 549685A DK 549685 A DK549685 A DK 549685A DK 549685 D0 DK549685 D0 DK 549685D0
Authority
DK
Denmark
Prior art keywords
difluornucleosides
neoplasm
treatment
difluoronucleosides
mammals
Prior art date
Application number
DK549685A
Other languages
English (en)
Other versions
DK549685A (da
DK162965C (da
DK162965B (da
Inventor
Gerald Burr Grindey
Larry Wayne Hertel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27101898&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK549685(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DK549685D0 publication Critical patent/DK549685D0/da
Publication of DK549685A publication Critical patent/DK549685A/da
Publication of DK162965B publication Critical patent/DK162965B/da
Application granted granted Critical
Publication of DK162965C publication Critical patent/DK162965C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
DK549685A 1984-12-04 1985-11-28 Anvendelse af et difluornucleosid eller et farmaceutisk acceptabelt salt deraf til fremstilling af et laegemiddel til behandling af neoplasma DK162965C (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67778384A 1984-12-04 1984-12-04
US67778384 1984-12-04
US78641985A 1985-10-10 1985-10-10
US78641985 1985-10-10

Publications (4)

Publication Number Publication Date
DK549685D0 true DK549685D0 (da) 1985-11-28
DK549685A DK549685A (da) 1986-06-05
DK162965B DK162965B (da) 1992-01-06
DK162965C DK162965C (da) 1992-06-01

Family

ID=27101898

Family Applications (1)

Application Number Title Priority Date Filing Date
DK549685A DK162965C (da) 1984-12-04 1985-11-28 Anvendelse af et difluornucleosid eller et farmaceutisk acceptabelt salt deraf til fremstilling af et laegemiddel til behandling af neoplasma

Country Status (21)

Country Link
US (1) US5464826A (da)
EP (1) EP0184365B1 (da)
JP (1) JPH0637394B2 (da)
KR (2) KR890003439B1 (da)
CN (1) CN1020194C (da)
AT (1) ATE92499T1 (da)
AU (1) AU581269B2 (da)
CA (1) CA1264738A (da)
CY (1) CY1806A (da)
DE (1) DE3587500T2 (da)
DK (1) DK162965C (da)
EG (1) EG17765A (da)
ES (1) ES8801546A1 (da)
GR (1) GR852858B (da)
HK (1) HK113693A (da)
HU (1) HU194273B (da)
IE (1) IE60328B1 (da)
IL (1) IL77133A (da)
NZ (1) NZ214364A (da)
PH (1) PH23172A (da)
PT (1) PT81559B (da)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) * 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
CA1295998C (en) * 1985-07-29 1992-02-18 Sai P. Sunkara Nucleosides and their use as antineoplastic agents
IL84842A0 (en) * 1986-12-24 1988-06-30 Lilly Co Eli Immunoglobulin conjugates
US4994558A (en) * 1986-12-24 1991-02-19 Eli Lilly And Company Immunoglobulin conjugates
US4814438A (en) * 1986-12-24 1989-03-21 Eli Lilly And Company Immunoglobulin conjugates of 2',2'-difluronucleosides
DE3856527T2 (de) * 1987-08-28 2002-10-31 Lilly Co Eli Stereoselektives Verfahren zur Herstellung von geschützten 2',2'-difluorlactonen
US5223608A (en) * 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US4965374A (en) * 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US4914028A (en) * 1988-02-10 1990-04-03 Eli Lilly And Company Method of preparing beta-2',2'-difluoronucleosides
US5644043A (en) * 1988-02-16 1997-07-01 Eli Lilly And Company 2',3'-dideoxy-2',2'-difluoronucleosides and intermediates
EP0329348B1 (en) * 1988-02-16 1995-07-12 Eli Lilly And Company 2',3'-Dideoxy-2',2'-difluoronucleosides
US4996308A (en) * 1988-03-25 1991-02-26 Merrell Dow Pharmaceuticals Inc. Derivatives with unsaturated substitutions for the 5'-hydroxymethyl group
JPH0232093A (ja) * 1988-06-08 1990-02-01 Merrell Dow Pharmaceut Inc 抗レトロウィルスジフルオロ化ヌクレオシド類
CA2004695C (en) * 1988-12-12 1999-08-10 Rosanne Bonjouklian Phospholipid nucleosides
AU4134793A (en) * 1992-06-22 1993-12-23 Eli Lilly And Company 2'-deoxy-2',2'-difluoro(2,6,8-substituted) purine nucleosides having anti-viral and anti-cancer activity and intermediates
YU43193A (sh) * 1992-06-22 1997-01-08 Eli Lilly And Company 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
US5424416A (en) * 1993-08-25 1995-06-13 Eli Lilly And Company Process for preparation of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-hydroxy protected-1-alkyl and aryl sulfonates and their use in preparation of 2',2'-difluoro-2'-deoxy nucleosides
US5480992A (en) * 1993-09-16 1996-01-02 Eli Lilly And Company Anomeric fluororibosyl amines
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5559222A (en) * 1995-02-03 1996-09-24 Eli Lilly And Company Preparation of 1-(2'-deoxy-2',2'-difluoro-D-ribo-pentofuranosyl)-cytosine from 2-deoxy-2,2-difluoro-β-D-ribo-pentopyranose
AU720451B2 (en) * 1997-01-24 2000-06-01 Conpharma As Gemcitabine derivatives
WO1998042351A1 (en) * 1997-03-24 1998-10-01 Eli Lilly And Company Difluoronucleoside phosphonic acids and derivatives thereof
TW466112B (en) * 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US20050281821A1 (en) * 1999-01-06 2005-12-22 Flavia Pernasetti Method and composition for angiogenesis inhibition
WO2000076497A1 (en) * 1999-06-14 2000-12-21 Cancer Research Ventures Limited Cancer therapy
JP2004505047A (ja) * 2000-07-28 2004-02-19 キャンサー・リサーチ・テクノロジー・リミテッド 複合治療による癌治療
GB0019124D0 (en) * 2000-08-03 2000-09-27 Pfizer Novel process
MX242553B (es) * 2000-10-20 2006-12-06 Eisai Co Ltd Derivados aromaticos que contienen nitrogeno.
AU2002234165A1 (en) * 2000-11-03 2002-05-27 Tularik, Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
US20050250854A1 (en) * 2000-11-03 2005-11-10 Amgen Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
US20030139373A1 (en) * 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
US7390885B2 (en) * 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
WO2003057217A1 (en) * 2002-01-14 2003-07-17 Novartis Ag Combinations comprising epothilones and anti-metabolites
AU2003235676A1 (en) * 2002-01-15 2003-07-30 Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
CN1646534A (zh) * 2002-02-14 2005-07-27 法玛塞特有限公司 修饰的氟化核苷类似物
GB2386836B (en) * 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
ATE508747T1 (de) * 2003-03-10 2011-05-15 Eisai R&D Man Co Ltd C-kit kinase-hemmer
EP1631258A1 (en) * 2003-05-20 2006-03-08 Aronex Pharmaceuticals Inc. Combination chemotherapy comprising gemcitabine and a liposomal platinum complex
WO2004105747A1 (en) * 2003-05-20 2004-12-09 Aronex Pharmaceuticals, Inc Combination chemotherapy comprising capecitabine and a liposomal platinum complex
DE10323279A1 (de) * 2003-05-21 2004-12-16 Stada Arzneimittel Ag Gebrauchsfertige Gemcitabin-Lösungen
GB0321999D0 (en) * 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations
JP4303726B2 (ja) * 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア誘導体およびその製造方法
US8318683B2 (en) * 2004-02-06 2012-11-27 Threshold Pharmaceuticals, Inc. Anti-cancer therapies
ATE538800T1 (de) * 2004-04-22 2012-01-15 Lilly Co Eli Kombinationstherapie zur krebsbehandlung
CN101001629B (zh) 2004-09-17 2010-05-05 卫材R&D管理有限公司 药物组合物
US20060089329A1 (en) * 2004-10-22 2006-04-27 Edgar Schridde Ready-to-use gemcitabine solution concentrates
US20060089328A1 (en) * 2004-10-22 2006-04-27 Edgar Schridde Ready-to-use gemcitabine solutions
US7563570B2 (en) * 2004-10-29 2009-07-21 Pangaea Biotech Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression
MX2007006837A (es) * 2004-12-08 2007-10-23 Sicor Inc Difluoronucleosidos y proceso de preparacion de los mismos.
DE102004063347A1 (de) * 2004-12-23 2006-07-13 Stada Arzneimittel Ag Gebrauchsfertige Gemcitabinlösungen und Gemcitabinlösungskonzentrate
TW200637870A (en) 2005-01-31 2006-11-01 Taiho Pharmaceutical Co Ltd Novel pyrimidine nucleoside compound and salt thereof
MX2007010316A (es) * 2005-03-04 2008-02-19 Dabur Pharma Ltd Intermediario de 21-desoxi, 21,21-difluoro-d-ribofuranosil nucleosidos enriquecidos en (-anomero y proceso para prepararlo.
US7485716B2 (en) 2005-05-02 2009-02-03 Pharmaessentia Corp. Stereoselective synthesis of β-nucleosides
EP1925941B1 (en) * 2005-08-01 2012-11-28 Eisai R&D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
US20070048325A1 (en) * 2005-08-24 2007-03-01 Dennis Van Epps Combination therapies for inhibiting integrin-extracellular matrix interactions
BRPI0614965A2 (pt) * 2005-08-26 2016-09-13 Antisoma Plc método para a modulação de crescimento neoplástico, usos de um composto ou, um sal, éster ou pró-droga farmaceuticamente aceitável do mesmo, de um aglutinante do fator de crescimento endotelial vascular, e de um taxano, formulação farmacêutica, e, kit
EP1949902B1 (en) * 2005-11-07 2012-06-27 Eisai R&D Management Co., Ltd. USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
WO2007061127A1 (ja) * 2005-11-22 2007-05-31 Eisai R & D Management Co., Ltd. 多発性骨髄腫に対する抗腫瘍剤
WO2007136103A1 (ja) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
EP2044939A1 (en) * 2006-06-29 2009-04-08 Eisai R&D Management Co., Ltd. Therapeutic agent for liver fibrosis
US20100216736A2 (en) 2006-07-21 2010-08-26 Taiho Pharmaceutical Co., Ltd. 2'-cyanopyrimidine nucleoside compound
EP2045258B1 (en) 2006-07-24 2011-09-21 Taiho Pharmaceutical Co., Ltd. 3'-ethynylcytidine derivative
EP2065372B1 (en) * 2006-08-28 2012-11-28 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
US8299046B2 (en) * 2006-11-17 2012-10-30 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
CA2670099A1 (en) * 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
AU2008205847A1 (en) 2007-01-19 2008-07-24 Eisai R & D Management Co., Ltd. Composition for treatment of pancreatic cancer
KR101445892B1 (ko) * 2007-01-29 2014-09-29 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암 치료용 조성물
US8765690B2 (en) * 2007-04-05 2014-07-01 Threshold Pharmaceuticals, Inc. Treatment of cancer with glufosfamide in patients not receiving insulin therapy
US20090048205A1 (en) * 2007-08-15 2009-02-19 Colin Meyer Combination therapy with synthetic triterpenoids and gemcitabine
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain vehicles, installations and methods
CN101883570B (zh) 2007-11-06 2013-06-19 药华医药股份有限公司 β-核苷的新颖合成
CA2705092A1 (en) 2007-11-07 2009-05-14 Schering Corporation Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
EP2218712B1 (en) 2007-11-09 2015-07-01 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
ME03529B (me) * 2008-01-11 2020-04-20 Reata Pharmaceuticals Inc Sintetički triterpenoidi i metode njihove upotrebe u tretmanu bolesti
MX2010008187A (es) * 2008-01-29 2010-08-10 Eisai R&D Man Co Ltd Uso combinado de inhibidor de angiogenesis y taxano.
CN102066398B (zh) 2008-04-18 2014-09-10 里亚塔医药公司 抗氧化剂炎症调节剂：c-17同系化齐墩果酸衍生物
NZ588709A (en) 2008-04-18 2012-11-30 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: triterpenoid oleanolic acid derivatives with saturation in the c-ring
MX339476B (es) 2008-04-18 2016-05-27 Reata Pharmaceuticals Inc Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
WO2009146216A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals. Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
ES2703274T3 (es) 2008-04-18 2019-03-07 Reata Pharmaceuticals Inc Moduladores de la inflamación antioxidantes: derivados del ácido oleanólico con modificaciones amino y otras en C-17
CA2724550C (en) 2008-05-22 2017-01-03 Kereos, Inc. Combination antitumor therapy
EP2309860B1 (en) 2008-07-22 2014-01-08 Trustees of Dartmouth College Monocyclic cyanoenones and methods of use thereof
US20110207680A1 (en) * 2008-08-13 2011-08-25 Curd John G Administration of Glufosfamide For The Treatment of Cancer
AR076263A1 (es) * 2009-04-06 2011-06-01 Eisai Inc Composiciones y metodos para tratar cancer. uso.
ES2593088T3 (es) * 2009-04-06 2016-12-05 Otsuka Pharmaceutical Co., Ltd. Derivados de (2'-Desoxi-Ribofuranosil)-1,3,4,7-Tetrahidro-(1,3)Diazepin-2-ona para Tratamiento de Cáncer
CA2757745C (en) * 2009-04-06 2018-02-13 Eisai Inc. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
EP2473041B1 (en) 2009-09-04 2018-03-07 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
EP2536720A1 (en) 2010-02-18 2012-12-26 Centro Nacional de Investigaciones Oncológicas (CNIO) Triazolo [4, 5 - b]pyridin derivatives
WO2011116026A2 (en) 2010-03-15 2011-09-22 The Board Of Trustees Of The University Of Illinois Inhibitors of beta integrin-g protein alpha subunit binding interactions
WO2011143593A1 (en) 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Conjugates of a lipoic acid derivative and anti-proliferation agent and medical uses thereof
WO2011143590A1 (en) 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent
US8530444B2 (en) * 2010-06-01 2013-09-10 Aposense Ltd. Pharmaceutical compounds
US9192680B2 (en) 2010-06-01 2015-11-24 Aposense Ltd. Pharmaceutical compounds
RU2560683C2 (ru) 2010-06-25 2015-08-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации
WO2012069972A1 (en) 2010-11-19 2012-05-31 Piramal Life Sciences Limited A pharmaceutical combination for the treatment of breast cancer
WO2012087943A2 (en) 2010-12-20 2012-06-28 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
TW201242597A (en) 2011-03-14 2012-11-01 Piramal Life Sciences Ltd A synergistic pharmaceutical combination for the treatment of pancreatic cancer
KR102021157B1 (ko) 2011-04-01 2019-09-11 제넨테크, 인크. Ａｋｔ 억제제 화합물 및 아비라테론의 조합물, 및 사용 방법
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
HUE038744T2 (hu) 2012-04-04 2018-11-28 Halozyme Inc Kombinációs terápia hialurodinázzal és egy tumor-targetált taxánnal
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
US9107926B2 (en) 2012-06-08 2015-08-18 Genentech, Inc. Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
EP2711009A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711008A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
EP2711007A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
WO2014078522A1 (en) 2012-11-14 2014-05-22 Ohio State Innovation Foundation Materials and methods useful for treating glioblastoma
CN104755463A (zh) 2012-12-21 2015-07-01 卫材R&D管理有限公司 非晶态形式的喹啉衍生物及其生产方法
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
US10080807B2 (en) 2014-06-09 2018-09-25 Lipomedix Pharmaceuticals Ltd. Combination chemotherapy comprising a liposomal prodrug of mitomycin C
RU2705299C2 (ru) 2014-06-26 2019-11-06 Ф. Хоффманн-Ля Рош Аг Антитела против 5-бром-2'-дезоксиуридина и способы применения
EP4089076A1 (en) 2014-08-28 2022-11-16 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
WO2016078160A1 (zh) * 2014-11-17 2016-05-26 常州方圆制药有限公司 胞苷衍生物及其应用
CN107835820B (zh) 2015-01-26 2021-10-15 芝加哥大学 识别癌症特异性IL13Rα2的CAR T细胞
US10308719B2 (en) 2015-01-26 2019-06-04 The University Of Chicago IL13Rα2 binding agents and use thereof in cancer treatment
CA2976325C (en) 2015-02-25 2023-07-04 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
KR20180018695A (ko) 2015-06-16 2018-02-21 가부시키가이샤 프리즘 파마 항암제
CN106317147B (zh) * 2015-07-06 2018-11-27 扬州硒瑞恩生物医药科技有限公司 核苷类化合物及其制备方法
US20200306254A1 (en) 2016-06-29 2020-10-01 Eli Lilly And Company Combination of erk1/2 inhibitor compound with gemcitabine or with gemcitabine and nab-paclitaxel for use in treatment of pancreatic cancer
US20180169120A1 (en) 2016-11-21 2018-06-21 Bexion Pharmaceuticals, Inc. Combination therapy including sapc-dops for the treatment of pancreatic cancer
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CA3049435A1 (en) 2017-01-09 2018-07-12 Scott Grindrod Selective histone deacetylase inhibitors for the treatment of human disease
CA3071599A1 (en) 2017-08-07 2019-02-14 Amgen Inc. Treatment of triple negative breast cancer or colorectal cancer with liver metastases with an anti pd-l1 antibody and an oncolytic virus
KR20200070238A (ko) 2017-09-18 2020-06-17 더 리전트 오브 더 유니버시티 오브 캘리포니아 클라우딘6 항체 및 암치료방법
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
BR112020015745A2 (pt) 2018-02-02 2020-12-08 Maverix Oncology, Inc. Conjugados de fármacos de moléculas pequenas de monofosfato de gemcitabina
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
CN111655710B (zh) 2018-06-29 2021-12-21 上海长乘医药科技有限公司 吉西他滨含磷前药
EP3853224A1 (en) 2018-09-20 2021-07-28 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
CN113453668A (zh) 2019-01-11 2021-09-28 利普麦迪克斯制药有限公司 包含丝裂霉素c的脂质体前药的脂质体组合物及其制备方法
SG11202109986TA (en) 2019-03-20 2021-10-28 Univ California Claudin-6 antibodies and drug conjugates
CA3132656A1 (en) 2019-04-30 2020-11-05 Instituto De Medicina Molecular Joao Lobo Antunes Rank pathway inhibitors in combination with cdk inhibitors
EP3980541A1 (en) 2019-06-04 2022-04-13 Apterna Limited Aptamers against transferrin receptor (tfr)
US20220305081A1 (en) 2019-06-24 2022-09-29 Amgen Inc. Inhibitions of sirp-gamma for cancer treatment
CN110684062B (zh) * 2019-10-18 2022-12-13 大连大学 一种治疗非小细胞肺癌的药物及其制备方法
GB202019692D0 (en) 2020-12-14 2021-01-27 Apterna Ltd Aptamer-sirna fusions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE147774C (da) *
US3705147A (en) * 1969-08-22 1972-12-05 Univ Utah 3-deazapyrimidine nucleosides and method of preparation thereof
US3870700A (en) * 1973-05-29 1975-03-11 Miles Lab 2-halogeno-2-deoxy-5-(substituted)uridines
JPS5136467A (en) * 1974-09-20 1976-03-27 Tanabe Seiyaku Co 11 beetaa dd2** harogeno 2** deokishiribofuranoshirurashirujudotai no seiho
DE2628202A1 (de) * 1976-06-23 1977-12-29 Max Planck Gesellschaft Verfahren zur herstellung von 2'-substituierten-d-ribofuranosylpurinderivaten
US4058602A (en) * 1976-08-09 1977-11-15 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis, structure, and antitumor activity of 5,6-dihydro-5-azacytidine
US4211773A (en) * 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
ZA859008B (en) * 1984-12-04 1987-07-29 Lilly Co Eli The treatment of tumors in mammals
CA1295998C (en) * 1985-07-29 1992-02-18 Sai P. Sunkara Nucleosides and their use as antineoplastic agents
US4914028A (en) * 1988-02-10 1990-04-03 Eli Lilly And Company Method of preparing beta-2',2'-difluoronucleosides
US4983724A (en) * 1988-02-16 1991-01-08 Eli Lilly And Company Inversion of 2,2-difluororibose to a 2,2-difluoroxylose and intermediates therefor
JPH0232093A (ja) * 1988-06-08 1990-02-01 Merrell Dow Pharmaceut Inc 抗レトロウィルスジフルオロ化ヌクレオシド類

Also Published As

Publication number Publication date
HU194273B (en) 1988-01-28
IL77133A (en) 1991-01-31
DE3587500D1 (de) 1993-09-09
IE60328B1 (en) 1994-06-29
EP0184365A2 (en) 1986-06-11
HUT39188A (en) 1986-08-28
IE853038L (en) 1986-06-04
KR890003439B1 (ko) 1989-09-21
JPS61148193A (ja) 1986-07-05
AU5055585A (en) 1986-06-12
CN1020194C (zh) 1993-03-31
KR890003426B1 (ko) 1989-09-20
CY1806A (en) 1995-09-08
CA1264738A (en) 1990-01-23
PT81559B (pt) 1988-03-03
DK549685A (da) 1986-06-05
PH23172A (en) 1989-05-19
DK162965C (da) 1992-06-01
EP0184365A3 (en) 1988-01-27
EG17765A (en) 1990-08-30
ATE92499T1 (de) 1993-08-15
DE3587500T2 (de) 1993-12-16
US5464826A (en) 1995-11-07
CN85109409A (zh) 1986-08-27
DK162965B (da) 1992-01-06
EP0184365B1 (en) 1993-08-04
ES549547A0 (es) 1987-08-01
AU581269B2 (en) 1989-02-16
HK113693A (en) 1993-10-29
GR852858B (da) 1986-03-28
NZ214364A (en) 1988-11-29
PT81559A (en) 1985-12-01
ES8801546A1 (es) 1987-08-01
JPH0637394B2 (ja) 1994-05-18
KR860004920A (ko) 1986-07-16

Similar Documents

Publication Publication Date Title
DK549685D0 (da) Difluornucleosider til behandling af neoplasma hos pattedyr
DK366785D0 (da) Fremgangsmaade til behandling af collagen-holdigt vaev
DK283881A (da) Fremgangsmaade til fremstilling af pyrazinyl1,2,4-oxadiazol-5-oner
DK496688D0 (da) Fremgangsmaade til behandling af organisk forurening
DK76185A (da) Forbedrede praeparater til behandling af psoriasis
DE3584013D1 (de) Zubereitung zur behandlung von psoriasis.
DK27485D0 (da) Fremgangsmaade til behandling af kvaeg
DK407889A (da) Fremgangsmaade til behandling af maelk
DK190584D0 (da) Fremgangsmaade til behandling af sojaboennemateriale
DK234590D0 (da) Fremgangsmaade til behandling af retrovirusinfektioner
DK329887D0 (da) Fremgangsmaade til behandling af asbest
ES2039847T3 (es) Leche hiperinmune antihipertensiva.
DK7184D0 (da) Fremgangsmade til diffusionsimpraegnering af traekonstruktioner
DE3584538D1 (de) Verfahren zur behandlung von textilien.
DK131585D0 (da) Fremgangsmaade til behandling af glaukom
DK4786D0 (da) Fremgangsmaade til behandling af biomasse
DK448489A (da) Fremgangsmaade til behandling af tekstiler
DK308788A (da) Fremgangsmaade til behandling af en aluminosilicatzeolit
DK36984D0 (da) Apparat til behandling af ar
DK219885D0 (da) Tetrahydronaphthalenoler til behandling af hypertension
DE3583337D1 (de) Zusammensetzung zur behandlung von haemorroiden.
IT8619935A1 (it) Procedimento per trattare maglieria
ATE51044T1 (de) Faerbschmelzverfahren von polyolefinen.

Legal Events

Date Code Title Description
PUP Patent expired